Compass Therapeutics, Inc. (NASDAQ:CMPX) Receives $11.38 Average Price Target from Brokerages

Compass Therapeutics, Inc. (NASDAQ:CMPX) has earned a consensus rating of “Moderate Buy” from the nine ratings firms that are currently covering the firm, MarketBeat reports. Two research analysts have rated the stock with a hold recommendation and seven have assigned a buy recommendation to the company. The average 12-month price target among brokerages that have issued ratings on the stock in the last year is $11.38.

A number of research analysts have weighed in on the company. Leerink Partners downgraded Compass Therapeutics from an “outperform” rating to a “market perform” rating and reduced their target price for the stock from $5.00 to $4.00 in a report on Friday, November 15th. Piper Sandler began coverage on Compass Therapeutics in a report on Wednesday, February 19th. They set an “overweight” rating and a $12.00 target price on the stock. Guggenheim initiated coverage on Compass Therapeutics in a research note on Monday, February 24th. They issued a “buy” rating and a $12.00 price target on the stock. Jefferies Financial Group raised their price objective on Compass Therapeutics from $7.00 to $8.00 and gave the company a “buy” rating in a research report on Monday, February 10th. Finally, D. Boral Capital reissued a “buy” rating and issued a $32.00 target price on shares of Compass Therapeutics in a report on Tuesday, February 25th.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of CMPX. Barclays PLC lifted its holdings in Compass Therapeutics by 195.4% during the third quarter. Barclays PLC now owns 170,245 shares of the company’s stock valued at $314,000 after purchasing an additional 112,614 shares in the last quarter. SG Americas Securities LLC lifted its holdings in shares of Compass Therapeutics by 921.6% in the fourth quarter. SG Americas Securities LLC now owns 395,017 shares of the company’s stock worth $573,000 after buying an additional 356,352 shares in the last quarter. Geode Capital Management LLC lifted its holdings in shares of Compass Therapeutics by 0.8% in the third quarter. Geode Capital Management LLC now owns 2,309,778 shares of the company’s stock worth $4,251,000 after buying an additional 19,095 shares in the last quarter. Bleakley Financial Group LLC lifted its holdings in shares of Compass Therapeutics by 250.7% in the fourth quarter. Bleakley Financial Group LLC now owns 39,993 shares of the company’s stock worth $58,000 after buying an additional 28,589 shares in the last quarter. Finally, The Manufacturers Life Insurance Company purchased a new position in shares of Compass Therapeutics in the third quarter worth $79,000. 68.43% of the stock is owned by hedge funds and other institutional investors.

Compass Therapeutics Price Performance

Shares of NASDAQ:CMPX opened at $2.51 on Friday. Compass Therapeutics has a 1 year low of $0.77 and a 1 year high of $4.08. The company has a market cap of $347.09 million, a PE ratio of -6.78 and a beta of 1.19. The stock’s 50-day moving average is $2.77 and its 200 day moving average is $2.03.

Compass Therapeutics (NASDAQ:CMPX) last posted its earnings results on Thursday, February 27th. The company reported ($0.11) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.01). Analysts expect that Compass Therapeutics will post -0.36 EPS for the current fiscal year.

Compass Therapeutics Company Profile

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.